In the global medical devices industry, there were 32 private equity deals announced in Q2 2023, worth a total value of $3.7bn, according to GlobalData’s Deals Database. The $2.1bn institutional buy-out (ibo) oneoncology by AmerisourceBergen and TPG Capital was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Medical Devices Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity increased by 891% in Q2 2023 compared with the previous quarter’s total of $373.5m and rose by 47% as compared to Q2 2022. Related deal volume increased by 28% in Q2 2023 versus the previous quarter and was 9% lower than in Q2 2022.
Notably, foreign direct investments (fdi)-related deals accounted for a 47% share of the global medical devices industry’s private equity deal activity in Q2 2023, up 150% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in Q2 2023 were Piper Sandler Companies; Houlihan Lokey; Canaccord Genuity Group with 3, 2, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Kirkland & Ellis; Allen & Overy; Latham & Watkins with 4, 2, 2 deals respectively.
For further understanding of GlobalData's Medical Devices Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.